Accelerating to Zero: Targeting Roadblocks to Achieve Malaria Elimination

Analysis of the effect of primaquine dose on efficacy, safety, and tolerability in patients with Plasmodium vivax malaria in Ethiopia: a systematic review and individual patient data meta-analysis

TS Degaga, K Thriemer, M Rajasekhar, T Abreha, A Assefa, NM Douglas, E Gadisa, A Hailu, J Hwang, GCKW Koh, MVG Lacerda, A Llanos-Cuentas, DA Mekonnen, JA Simpson, FG Tadesse, WRJ Taylor, L von Seidlein, A Woyessa, AK Yeshiwondim, D Yilma

2026-12-01

Background: The 8-aminoquinoline antimalarials are used to prevent P. vivax relapses. Recent evidence suggests high total dose pri..

Protective immunity to clinical malaria is modified by the genetic diversity of P. falciparum antigens

MT Naung, R Mazhari, RJ Longley, S Mehra, W Wong, P Bareng, M Laman, B Kiniboro, M Ome-Kaius, P Michon, J Beeson, E Takashima, H Nagaoka, S Takala-Harrison, T Tsuboi, LJ Robinson, I Mueller, AE Barry

2026-10-01

Prioritising malaria vaccine targets requires understanding immunity to genetically and structurally diverse parasite antigens, in..

Identifiability and model misspecification for modelling recurrent infections using routine health care data

AWC Yan, JA Flegg, JR Poespoprodjo, NM Douglas, RN Price, A Devine, DJ Price, RH Chisholm

2026-09-01

For infectious diseases where people can experience multiple infections during their lifetime, the time between observed infection..

Short-Course Low-Dose Primaquine for Radical Cure in G6PD-Normal Patients in the Pre-Elimination Context of Nepal

P Ghimire, G Dahal, N Adhikari, KR Rijal, S Adhikari, MR Banjara, H Mnjala, G Lee, S Weston, A Rumaseb, A Rai, B Ley, MS Hossain, JA Simpson, M Rajasekhar, B Adhikari, RN Price, BK Lal, K Thriemer

2026-08-01

Background: Plasmodium vivax remains a challenge for malaria elimination in Nepal due to its ability to relapse. Radical cure with..

Effect of higher dose primaquine for the radical cure of Plasmodium vivax malaria in Indonesia: a systematic review and individual patient data meta-analysis

I Fadilah, JA Watson, AP Pasaribu, I Sutanto, EJ Nelwan, K Lidia, M Rajasekhar, IR Elyazar, WR Taylor, K Thriemer, NP Day, JR Poespoprodjo, JA Simpson, RN Price, JK Baird, RJ Commons

2026-07-01

Background: Plasmodium vivax malaria has diverse transmission and relapse patterns in Indonesia. The optimal dose of primaquine to..

Assessing the effect of parasite antigen genetic diversity on performance of Plasmodium vivax serological exposure markers for malaria: a multicentre observational diagnostic accuracy study

APN Bareng, KW Wu, E Takashima, DC Argyropoulos, L Smith, MT Naung, R Mazhari, K Schoffer, N Kiernan-Walker, A Abraham, M Lamont, S Mehra, PS Lim, J Sattabongkot, W Monteiro, M Lacerda, J Healer, CE Chitnis, WH Tham, T Tsuboi

2026-06-01

Background Plasmodium vivax poses a major obstacle to malaria elimination because this parasite can lie dormant in the liver for w..

Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial

TS Degaga, AP Pasaribu, R Tripura, N Ghanchi, M Rajasekhar, B Adhikari, B Ley, SA Bamboro, FA Jabbar, N Hasibuan, TT Tego, S Zehra, B Qurashi, H Mnjala, G Lee, P Li, AM Kazi, W Safitri, Y Yulita, DSP Siagian

2026-06-01

Background: Shorter courses of primaquine and single-dose tafenoquine have potential to improve the prevention of recurrent Plasmo..

Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trial

A Hysa, DH Opi, J Waterhouse, S Chishimba, JL Horton, N Kingston, HJ Netter, D Wetzel, M Piontek, G Feng, J Sacarlal, C Dobaño, L Kurtovic, JG Beeson

2026-05-01

Background The RTS,S/AS01 malaria vaccine was recently approved for implementation in children, but only provides modest and short..

A longitudinal study of children identifies antibody Fc-mediated functions and antigen targets of immunity to Plasmodium vivax malaria

DH Opi, RJ Longley, E Takashima, T Spelman, Y Tayipto, K Schoffer, J Brewster, L Reiling, BD Wines, B Kiniboro, P Siba, M Harbers, M Hogarth, T Tsuboi, LJ Robinson, I Mueller, JG Beeson

2026-03-10

Understanding immunity against Plasmodium vivax, a leading cause of malaria, will accelerate development of vaccines, which are cu..

The role of the spleen in red blood cell loss caused by malaria: A mathematical model

R Moss, S Dini, S Kho, BE Barber, PA Buffet, M Rajasekhar, DJ Price, NM Anstey, JA Simpson

2026-01-12

The human spleen significantly influences red blood cell (RBC) dynamics due to its ability to retain and/or remove RBCs from perip..

Quantification of cure for pharmacodynamic models of antimalarial drugs: Deterministic versus stochastic approaches

MK Tully, RJ Commons, JA Simpson, DJ Price

2026-01-01

In silico pharmacokinetic–pharmacodynamic (PK–PD) models are used to inform dose optimisation in antimalarial drug development. He..

Seven-day versus fourteen-day low-dose primaquine for Plasmodium vivax malaria in India: an open-label, non-inferiority, randomised, controlled trial

RK Baharia, S Singh-Phulgenda, SM Naser, A Gupta, R Chhajed, MS Hossain, K Yadav, R Verma, SK Pal, PH Ranjit, B Solanki, KJ Upadhyay, L Dabhi, R Sharma, SR Chowdhury, A Chakravorty, M Rajasekhar, G Lee, H Mnjala, S Ghosh

2026-01-01

Background India has a high burden of Plasmodium vivax malaria. Current malaria treatment guidelines recommend a total primaquine ..

How to use learning curves to evaluate the sample size for malaria prediction models developed using machine learning algorithms

SG Zaloumis, M Rajasekhar, JA Simpson

2025-12-01

Background: Machine learning algorithms have been used to predict malaria risk and severity, identify immunity biomarkers for mala..

Navigating parasite antigen genetic diversity in the design of Plasmodium vivax serological exposure markers for malaria.

Paolo Bareng, Kenneth W Wu, Eizo Takashima, Dionne Argyropoulos, Lauren Smith, Myo Naung, Ramin Mazhari, Kael Schoffer, Nicholas Kiernan-Walker, Anju Abraham, Macie Lamont, Somya Mehra, Pailene Lim, Jetsumon Sattabongkot, Wuelton Monteiro, Marcus Lacerda, Julie Healer, Chetan E Chitnis, Wai-Hong Tham, Takafumi Tsuboi

2025-07-08

BACKGROUND: Plasmodium vivax poses a major obstacle to malaria elimination because it can lie dormant in the liver for weeks or mo..

Human antibodies against Anopheles salivary proteins: emerging biomarkers of mosquito and malaria exposure

EA Kearney, AS Heng-Chin, K O'Flaherty, FJI Fowkes

2025-05-01

Antibodies developed against Anopheles mosquito salivary proteins injected during biting may serve as proxy biomarkers of Anophele..

Within-host modeling of primaquine-induced hemolysis in hemizygote glucose-6-phosphate dehydrogenase deficient healthy volunteers

JA Watson, P Mehdipour, R Moss, P Jittamala, S Zaloumis, DJ Price, S Dini, B Hanboonkunupakarn, P Leungsinsiri, K Poovorawan, K Chotivanich, G Bancone, RJ Commons, NPJ Day, S Pukrittayakamee, WRJ Taylor, NJ White, JA Simpson

2025-04-01

Primaquine is the only widely available drug to prevent relapses of Plasmodium vivax malaria. Primaquine is underused because of c..

Systematic review and individual patient data meta-analysis on glucose- 6 – phosphate dehydrogenase activities measured by a semi-quantitative handheld biosensor

B Ley, LR Vasquez, A Sitsabasan, B Adhikari, N Adhikari, MS Alam, S Das, P Ghimire, MVG Lacerda, RN Price, KR Rijal, L von Seidlein, A Talukdar, K Thriemer, AW Satyagraha, A Sadhewa, M Rajasekhar, RJ Commons

2025-01-01

Background: Measurement of glucose-6-phosphate dehydrogenase (G6PD) activity guides hypnozoitocidal treatment of P vivax malaria. ..

Evaluation of a Bayesian hierarchical pharmacokinetic–pharmacodynamic model for predicting parasitological outcomes in Phase 2 studies of new antimalarial drugs

MK Tully, S Dini, JA Flegg, JS McCarthy, DJ Price, JA Simpson

2024-09-01

The rise of multidrug-resistant malaria requires accelerated development of novel antimalarial drugs. Pharmacokinetic–pharmacodyna..

Geospatial joint modeling of vector and parasite serology to microstratify malaria transmission

EA Kearney, P Amratia, SY Kang, PA Agius, KA Alene, K O’Flaherty, WH Oo, JC Cutts, W Htike, D Da Silva Goncalves, Z Razook, AE Barry, D Drew, A Thi, KZ Aung, HK Thu, MM Thein, NN Zaw, WYM Htay, AP Soe

2024-06-11

The World Health Organization identifies a strong surveillance system for malaria and its mosquito vector as an essential pillar o..